Strand seeks US approval for blood cancer test
In short
Strand is looking for US FDA approval for its blood cancer screening test, CancerSpot, and wants to expand into Southeast Asia.
The company also plans to bring the price in India below ₹10,000 in the next two to three years, which could make the test more accessible.
What the reporting says
Strand, the Reliance-backed genomics company, is pursuing US FDA approval for its blood-based cancer screening test, CancerSpot, and is also targeting Southeast Asia markets. The reported plan points to a broader commercial rollout if approvals and pricing goals are achieved.
Why it matters
Strand, the Reliance-backed genomics company, is seeking US FDA approval for CancerSpot and is targeting markets in the US and Southeast Asia. The reported India pricing goal is to bring the test below ₹10,000 over the next two to three years. If achieved, that could affect access and adoption for patients and buyers considering blood-based cancer screening.